Clinical trials: NYHA Class II Heart Failure
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study.
- Trial name
- ALLEVIATE-HF (NCT04452149)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention
- Where
- 53 sites in United States
- Volunteers
- 826 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Comprehensive Hybrid Cardiac Rehabilitation Trial on Heart Failure
CO-CREATION-HF aims to evaluate the effectiveness of a comprehensive and hybrid cardiac rehabilitation model compared to supervised exercise alone.
- Trial name
- COCREATIONHF (NCT06313684)
- Testing
- Comprehensive Initial Assessment, Continuous evaluation, Interval Exercise
- Where
- 4 sites in Chile
- Volunteers
- 152 people
- Sponsor
- Universidad de La Frontera
Heart Failure NYHA Class II
Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure
This study is designed to compare between blood flow restricted resistance exercises and low level laser on cardiac functions in patients with chronic heart failure
- Trial name
- heart failure (NCT07045038)
- Testing
- Acupuncture LLLT:, Blood flow restricted resistance exercise:, Medical treatment
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Heart Failure, Iron-deficiency
Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency
The goal of this randomized, controlled, open-label, interventional study is to evaluate whether, in patients with heart failure (HF) and iron deficiency (ID), the administration of vitamin D in combination with sucrosomial iron…
- Conditions
- Heart Failure, Iron-deficiency, Heart Failure, Systolic, Heart Failure NYHA Class II
- Trial name
- VICTORID-HF (NCT05702970)
- Testing
- Sucrosomial iron, Vitamin D, Ferric Carboxymaltose 50 MG/ML
- Volunteers
- 258 people
- Sponsor
- University of Padova
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Congestive Heart Failure
Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema
The study consists in two treatment groups, one group will receive Diurisa® (furosemide 40 mg + amiloride chloride 10 mg) and the other one will receive furosemide 40 mg (Lasix®)
- Trial name
- NCT01210365
- Testing
- Diurisa®, Lasix ®
- Where
- 4 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- Eurofarma Laboratorios S.A.
Heart Failure
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
This is a single-arm, open label, interventional, multi-center, phase 4 pilot study.
- Trial name
- Biso-CHF (NCT03026088)
- Testing
- Bisoprolol
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Heart Failure
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack.
- Trial name
- EMPHASIS-HF (NCT00232180)
- Testing
- Eplerenone
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 2,743 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Heart Failure NYHA Class II
Nutritional Therapy Interventions in Heart Failure
The investigators will examine the effects of 12-weeks of nutritional interventions in older participants who have a symptom of mild to moderate heart failure.
- Trial name
- NCT03424265
- Testing
- EAA mixture
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Arkansas
Heart Failure, Heart Failure NYHA Class I
Promoting Well-being and Health in Heart Failure
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24…
- Conditions
- Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT04829617
- Testing
- PP-MI Intervention, MI-alone Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Massachusetts General Hospital
Heart Failure, Heart Failure NYHA Class III
HEart fAiluRe evaluaTion Questionnaire
The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class I
- Trial name
- HEART (NCT03895073)
- Testing
- healthy volunteers
- Where
- Greece
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- John Parissis
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors.
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Trial name
- EMAS-HF (NCT05885607)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
Aldosterone antagonists or mineralocorticoid receptor antagonists (MRAs) are used as therapeutic agents for the management of HF with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT06641284
- Testing
- Spironolactone
- Where
- Saudi Arabia
- Volunteers
- 509 people
- Sponsor
- Ahmad Abdullah Salawi
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure NYHA Class II, Heart Failure NYHA Class III
A Study to Improve Physician-Youth Communication and Medical Decision Making
The goal of this study is improving patient-centered communication for young people with advanced heart disease.
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- CHATT (NCT05835063)
- Testing
- We Chatt communication tool, Usual/standard care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Michigan
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Cognitive Intervention to Improve Memory in Heart Failure Patients
Cognitive Intervention to Improve Memory in Heart Failure patients
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class I
- Trial name
- Memoir-HF (NCT03035565)
- Testing
- Computerized Cognitive Training with Brain HQ, Computerized Crossword Puzzles
- Where
- 2 sites in United States
- Volunteers
- 276 people
- Sponsor
- Indiana University
Heart Failure NYHA Class I, Heart Failure NYHA Class II
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT03005184
- Testing
- Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid
- Where
- United States
- Sponsor
- Vanderbilt University Medical Center
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Biomarker Study: Heart Failure Patients at Risk
In order to determine if NfL can be a prognostic biomarker for VCID, participants will undergo a baseline evaluation consisting of neuropsychological testing and a blood draw with a 12-month follow-up consisting of…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT05336175
- Testing
- Angiotensin 1-7, Saline solution
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona